secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2025-11-21T23:59:59+00:00
Accession:  0001493152-25-024691
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma CFO Keith Kucinski to resign effective Jan 17, 2026
---------------------------------------------------------------------

- Keith Kucinski notified his resignation as CFO on Nov 18, 2025.
- Resignation effective Jan 17, 2026; he is pursuing other opportunities.
- No disagreement with the Company regarding operations, policies, or practices.
- No successor named; CEO Jerome Jabbour signed the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315225024691/0001493152-25-024691-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315225024691/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-024691

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer